RAD-140
Also known as: Testolone
RAD-140 is a nonsteroidal selective androgen receptor modulator. It binds androgen receptors and is being studied for tissue-selective androgen signaling, but human data remain early and oncology-focused, so performance claims should remain conservative and risk-aware.
- A First-in-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2- Metastatic Breast Cancer.
Clinical breast cancer · 2022 · PMID 34565686
Selective androgen receptor modulator. Originally investigated for muscle wasting. Phase 1 trials completed. Research chemical — not approved for human use.
Post-cycle therapy strongly recommended due to HPG axis suppression. Longer cycles compound liver and suppression risks.
Off-cycle: 8 weeks
Half-life ~60 hours allows once-daily dosing.
Contraindications
- • Liver disease
- • Cardiovascular disease
- • Prostate cancer
- • Pregnancy
- • History of hormone-sensitive cancers
Common side effects
- • HPG axis suppression
- • Hair shedding (dose-dependent)
- • Aggression
- • Sleep disturbance
- • Headache
Serious risks
- • Hepatotoxicity — case reports of drug-induced liver injury
- • Significant testosterone suppression
- • HDL cholesterol reduction
- • Potential cardiovascular strain
Drug interactions
- • Avoid with other hepatotoxic compounds (alcohol, 17-alpha-alkylated steroids)
Requires monitoring
- • Liver function (ALT/AST) at baseline, mid-cycle, and post
- • Total and free testosterone
- • Lipid panel
Pregnancy / breastfeeding
Contraindicated
Male
Strong HPG suppression — post-cycle therapy typically required
Female
Not generally recommended — virilization risk and insufficient female safety data
- Not a steroid — but hepatotoxicity and suppression are real and documented
- PCT is not optional for most users
- Do not stack with other SARMs or 17-alpha-alkylated orals — compound hepatotoxicity
Sign in to calculate your dose, add this compound to your stack, and check for interactions with your current cabinet.